HLA-A and B-cell chronic lymphocytic leukemia: When univariate Kaplan–Meier analyses were performed, the following variables were found to be associated with 15-year treatment requirement: 1) unmutated IGHV status (84% vs. 22%, P<0.0001), 2) intermediate/high-risk cytogenetics (85% vs. 38%, P<0.0001), 3) high β2-microglobulin level (67% vs. 38%, P<0.0001), 4) Binet A CLL diagnosis rather than hiMBL (56% vs. 27%, P<0.0001), 5) age ≤60 years (57% vs. 32%, P<0.01), and 6) HLA-A*24 (61% vs. 38%, P = 0.017) (see Table 2).